Cerenome, Inc. (CNSY)
0.6427
-0.03
(-4.06%)
USD |
NASDAQ |
Nov 06, 16:00
0.6601
+0.02
(+2.71%)
After-Hours: 20:00
Cerenome Cash from Operations (Quarterly) : -7.132M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -7.132M |
| March 31, 2026 | -6.238M |
| December 31, 2025 | -6.257M |
| September 30, 2025 | -2.548M |
| June 30, 2025 | -5.798M |
| March 31, 2025 | -6.172M |
| December 31, 2024 | -1.211M |
| September 30, 2024 | -3.68M |
| June 30, 2024 | -1.15M |
| March 31, 2024 | -4.513M |
| December 31, 2023 | -1.881M |
| September 30, 2023 | -2.399M |
| June 30, 2023 | -2.778M |
| March 31, 2023 | -5.793M |
| December 31, 2022 | -2.234M |
| September 30, 2022 | -4.222M |
| June 30, 2022 | -2.64M |
| March 31, 2022 | -3.876M |
| December 31, 2021 | -2.624M |
| September 30, 2021 | -2.251M |
| June 30, 2021 | -2.399M |
| March 31, 2021 | -3.006M |
| December 31, 2020 | -3.224M |
| September 30, 2020 | -2.299M |
| June 30, 2020 | -1.409M |
| Date | Value |
|---|---|
| March 31, 2020 | -1.502M |
| December 31, 2019 | 1.036M |
| September 30, 2019 | -2.118M |
| June 30, 2019 | -1.554M |
| March 31, 2019 | -3.27M |
| December 31, 2018 | -2.488M |
| September 30, 2018 | -2.647M |
| June 30, 2018 | -2.721M |
| March 31, 2018 | -4.119M |
| December 31, 2017 | -4.224M |
| September 30, 2017 | -4.049M |
| June 30, 2017 | -5.028M |
| March 31, 2017 | -4.827M |
| December 31, 2016 | -4.161M |
| September 30, 2016 | -4.637M |
| June 30, 2016 | -5.677M |
| March 31, 2016 | -5.058M |
| December 31, 2015 | -4.522M |
| September 30, 2015 | -6.158M |
| June 30, 2015 | -4.758M |
| March 31, 2015 | -5.03M |
| December 31, 2014 | -4.956M |
| September 30, 2014 | -7.237M |
| June 30, 2014 | -9.175M |
| March 31, 2014 | -8.962M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 340.98M |
| Ernexa Therapeutics, Inc. | -4.152M |
| ACADIA Pharmaceuticals, Inc. | -- |
| Anika Therapeutics, Inc. | -0.684M |
| Savara, Inc. | -29.75M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 5.366M |
| Cash from Financing (Quarterly) | 1.11M |
| Free Cash Flow | -23.55M |
| Free Cash Flow Per Share (Quarterly) | -1.106 |
| Free Cash Flow to Equity (Quarterly) | -6.95M |
| Free Cash Flow to Firm (Quarterly) | -7.626M |
| Free Cash Flow Yield | -626.6% |